Marty Schenker

Senior Counsel
Full contact info

I focus on high-stakes disputes, and have delivered wins to clients in many multi-billion dollar and bet-the-company cases.

Experience

Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals

July 14, 2022

Cooley advised ViaCyte, a biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for Type 1 diabetes (T1D), on its definitive agreement to be acquired by global biotechnology company Vertex Pharmaceuticals for $320 million in cash. Partners Rowook Park and Carlos Ramirez, along with associate Lindsey O’Crump, led the Cooley team advising ViaCyte.

Read more

Related contacts

Rowook Park
Partner, San Diego
Carlos Ramirez
Partner, San Diego
Jacqueline Grise
Partner, Washington DC
Rama Padmanabhan
Partner, San Diego
Marty Schenker
Senior Counsel , San Francisco
Todd Gluth
Partner, San Diego
Blake Martell
Partner, San Francisco
Kay Chandler
Partner, San Diego
Charity Williams
Partner, San Diego
Jeffrey Karr
Partner, Palo Alto
Ross Eberly
Partner, Los Angeles Santa Monica
Phil Mitchell
Partner, New York
Natasha Leskovsek
Of Counsel, Washington DC
David Burns
Special Counsel, Washington DC
Dina Andrawess
Special Counsel, Palo Alto
Stella Sarma
Special Counsel, Brussels
Arman Sagart
Associate, San Diego
Lindsey O'Crump
Associate, Washington DC
Melissa Meza
Associate, San Diego
Joe Mandry
Associate, San Diego
Julia R. Brinton
Associate, Washington DC
Kimberley Scimeca
Associate, Boston
Daniel Lac
Associate, San Diego
Amanda Griggs
Associate, New York

Related Practices & Industries

Cooley Successfully Represents PG&E in One of the Most Complex Bankruptcy Confirmation Proceedings in History

November 1, 2016

Successfully represented Pacific Gas and Electric in its bankruptcy confirmation trial, widely believed to be one of the most complex confirmation proceedings in the history of the US Bankruptcy Courts. The case concluded with the confirmation of PG&E's bankruptcy plan, enabling the company to emerge from bankruptcy.

Related contacts

Marty Schenker
Senior Counsel , San Francisco

Related Practices & Industries

Medivation Agrees to Sell to Pfizer for $14 Billion

August 23, 2016

Cooley is advising biopharmaceutical company Medivation on its agreement to sell to Pfizer for approximately $14 billion. The transaction is expected to close in the third or fourth quarter. Prior to the announced agreement, Cooley also advised Medivation as the target of a hostile takeover bid by Sanofi.

Read more

Related contacts

Jamie Leigh
Partner, San Francisco
Kenneth Guernsey
Senior Counsel , San Francisco
Barbara Kosacz
Senior Counsel, Palo Alto
Marty Schenker
Senior Counsel , San Francisco
Patrick Gibbs
Partner, Palo Alto
Jacqueline Grise
Partner, Washington DC
Barbara Mirza
Partner, Los Angeles Santa Monica
Thomas Welk
Senior Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington DC
Brett White
Of Counsel, Palo Alto
Sarah Lightdale
Partner, New York
Cydney Posner
Special Counsel, San Francisco
Ben Beerle
Partner, San Francisco
Anne Lieberman
Partner, Los Angeles Santa Monica

Related Practices & Industries

Cooley Successfully Resolves Qualcomm’s Global Licensing Dispute with Nokia through Multi-Billion Dollar Deal

July 14, 2014

Successfully represented Qualcomm in its global patent-licensing dispute with Nokia concerning Qualcomm's cellular communications technology. The case settled favorably for Qualcomm at the start of trial, resulting in a 15-year multibillion-dollar license agreement between Qualcomm and Nokia.

Related contacts

Marty Schenker
Senior Counsel , San Francisco

Related Practices & Industries

Complete win for Gilead Sciences in dispute involving breakthrough SOVALDI treatment

July 1, 2014

When F. Hoffmann-La Roche sought to strip Gilead of its rights to a blockbuster drug, Gilead turned to Cooley. At stake were Gilead's exclusive rights to sofosbuvir (Sovaldi), approved by the FDA in 2013 as a breakthrough drug for the treatment of hepatitis C. Within the first six months of going to market, Sovaldi earned nearly $6 billion in sales, making it one of the most successful drug launches in history.

Roche alleged exclusive rights based on an earlier collaboration agreement. Cooley presented this "bet the company" case before a panel of three arbitrators during a two-week arbitration hearing. In August 2014, the arbitration panel issued its award, ruling in favor of Gilead and finding that Roche failed to establish any of its contract or patent-based claims to sofosbuvir. This was a huge win for Gilead, with Sovaldi generating billions of dollars in revenue each year.

The Financial Times, The American Lawyer and its sister publications The Recorder and National Law Journal all profiled the victory when announcing Cooley as the winner of multiple litigation awards, including AmLaw's recent selection of the case as "Global Dispute of the Year: Commercial Arbitration."

Related contacts

Stephen Neal
Chairman Emeritus, Palo Alto
Marty Schenker
Senior Counsel , San Francisco
Dr. Michelle Rhyu
Partner, Palo Alto
Jeffrey Karr
Partner, Palo Alto
Daniel Knauss
Partner, Palo Alto

Related Practices & Industries

View more

Rankings & accolades

Lawyers' Committee for Civil Rights Father Cuchulain Moriarty Award (2021)

American Lawyer: Global Dispute of the Year – Commercial Arbitration (2015)

Northern California Super Lawyers (2006-2016)

Financial Times: Innovative Lawyers

Memberships & affiliations

American Bar Association

The Bar Association of San Francisco